Business
Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus
Theralase® Technologies Inc. is currently seeking partnerships / licensing opportunities in ...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex VirusTheralase® Technologies Inc. is currently seeking partnerships / licensing opportunities in the commercial development of this latest discoveryTORONTO, ON / ACCESSWIRE / September 3, 2024 / Theralase® Technologies Inc. (\"Theralase®\" or the \"Company\") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it's lead drug formulation, Ruvidar TM , has been demonstrated preclinically to be more effective in the destruction of the Herpes Simplex Virus 1 (\"HSV-1\") than the currently approved standard of care drug, Acyclovir.Acyclovir is an antiviral drug used to slow the growth and spread of the HSV-1 virus in the body. Acyclovir will not cure herpes, but it can lessen the symptoms of the infection. It is used to treat infections caused by herpes viruses, such as genital herpes, cold sores, shingles and chicken pox.The globalantiviral drugs market sizeis expected to be worth around $ USD 71.1 Billion by 2032.An estimated 3.7 billion people under age 50 (67%) globally have HSV-1, the main cause of oral herpes.As an indication of the impact that a virus can have on the human population, since early 2020, the SARS-CoV-2 virus (COVID-19) has been estimated to have been responsible for over 250 million infections and 5 million deaths.In previous experiments, conducted at the University of Manitoba, it was demonstrated that the light-activated small molecule Ruvidar TM was highly effective in inactivating numerous viruses.The latest research now demonstrates that Ruvidar TM is more potent than Acyclovir, the gold-standard anti-herpetic treatment, in destroying an ongoing HSV-1 infection. See Figure 1. Another very important observation from the experiment is that Acyclovir was unable to prevent HSV-1 replication, if added one day after infection; however, Ruvidar TM was able to prevent HSV-1 replication by 10 million-fold when added 1 day after infection. See Figure 2.In other words, from a clinical perspective, if a patient has pre-existing HSV-1, then Acyclovir would be unable t...